All lobbying filings

NVG, LLC

NVG, LLC filed a Q3 report for Novo Nordisk Inc. on October 20, 2026, reporting $80,000 in lobbying income.

Lobbying for Novo Nordisk Inc. · Pharmaceutical company

As filed: NVG, LLC for NOVO NORDISK INC.

All filings by NVG, LLC · Everything Novo Nordisk Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to pharmaceutical supply chain transparency and integrity. Issues related to compounding and counterfeit medicines.

Medicare/Medicaid

Issues related to Medicare coverage of Anti-Obesity Medicines.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.